Showing results (191-200 of 203) with videos related to
Sort By:
Pageof 21
British Journal of Cancer|October 21, 2023
Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortiumJessica L Petrick, Charlotte E Joslin, Courtney E Johnson, et al.The Journal of Clinical Endocrinology and Metabolism|September 10, 2010
Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutismRichard S Legro, William D Schlaff, Michael P Diamond, et al.Journal of Women'S Health (2002)|January 13, 2023
A Comparative Analysis of Health-Related Quality of Life 1 Year Following Myomectomy or Uterine Artery Embolization: Findings from the COMPARE-UF RegistryRaymond M Anchan, Daniel Wojdyla, Pietro Bortoletto, et al.Journal of Lower Genital Tract Disease|March 16, 2012
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerDebbie Saslow, Diane Solomon, Herschel W Lawson, et al.American Journal of Obstetrics and Gynecology|May 27, 2023
Long-term health-related quality of life and symptom severity following hysterectomy, myomectomy, or uterine artery embolization for the treatment of symptomatic uterine fibroidsRaymond M Anchan, James B Spies, Shuaiqi Zhang, et al.Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2017
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based OutreachGoli Samimi, Marcus Q Bernardini, Lawrence C Brody, et al.BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.Pageof 21